C
Clemens Decristoforo
Researcher at Innsbruck Medical University
Publications - 214
Citations - 9217
Clemens Decristoforo is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Biodistribution & Medicine. The author has an hindex of 48, co-authored 197 publications receiving 7907 citations. Previous affiliations of Clemens Decristoforo include University of Innsbruck & Heidelberg University.
Papers
More filters
Journal ArticleDOI
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
Michael Gabriel,Clemens Decristoforo,Dorota Kendler,Georg Dobrozemsky,Dirk Heute,Christian Uprimny,Peter Kovacs,Elisabeth von Guggenberg,Reto Bale,Irene Virgolini +9 more
TL;DR: 68Ga-DOTA-TOC PET shows a significantly higher detection rate compared with conventional somatostatin receptor scintigraphy and diagnostic CT with clinical impact in a considerable number of patients and showed higher diagnostic efficacy compared with SPECT.
Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
Michael Gabriel,Clemens Decristoforo,Dorota Kendler,Georg Dobrozemsky,Dirk Heute,Christian Uprimny,Peter Kovacs,Elisabeth von Guggenberg,Reto Bale,Irene Virgolini +9 more
TL;DR: In this article, the authors compared the performance of PET and CT in patients with known or suspected neuroendocrine tumors and found that PET showed higher diagnostic efficacy compared with SPECT and CT.
Journal ArticleDOI
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
Murat Bozkurt,Irene Virgolini,Sona Balogova,Sona Balogova,Mohsen Beheshti,Mohsen Beheshti,Domenico Rubello,Clemens Decristoforo,Valentina Ambrosini,Andreas Kjaer,Roberto Delgado-Bolton,Jolanta Kunikowska,Wim J.G. Oyen,Arturo Chiti,Francesco Giammarile,Anders Sundin,Stefano Fanti +16 more
TL;DR: This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.
Journal ArticleDOI
68 Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Francesco Ceci,Francesco Ceci,Christian Uprimny,Bernhard Nilica,Llanos Geraldo,Dorota Kendler,Alexander Kroiss,Jasmin Bektic,Wolfgang Horninger,Peter Lukas,Clemens Decristoforo,Paolo Castellucci,Stefano Fanti,Irene Virgolini +13 more
TL;DR: The great potential of 68Ga-PSMA PET/CT in patients with rPCa and BR was confirmed and PSA and PSAdt were valuable predictors of pathological 68Ga/CT findings.
Journal ArticleDOI
68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
Christian Uprimny,Alexander Kroiss,Clemens Decristoforo,Josef Fritz,Elisabeth von Guggenberg,Dorota Kendler,Lorenza Scarpa,Gianpaolo di Santo,Llanos Geraldo Roig,Johanna Maffey-Steffan,Wolfgang Horninger,Irene Virgolini +11 more
TL;DR: The GS and PSA level correlated with the intensity of tracer accumulation in the primary tumours of PC patients on 68Ga-PSMA-11 PET/CT, which should be preferentially applied for primary staging of PC in patients with GS >7 or PSA levels ≥10 ng/ml.